Updates are available Correction dated 2025-08-04
Click to view Correction: https://doi.org/10.1007/s12265-025-10674-3
-
Authors
Ferreira Felix, Iuri
Karlinski Vizentin, Vanessa
Alzate-Aguirre, Mateo
Patel, Mehrie
Geske, Jeffrey B.
Araoz, Phillip
Giudicessi, John R.
Ommen, Steve R.
Arruda-Olson, Adelaide M.
Ackerman, Michael J.
Bos, J. Martijn https://orcid.org/0000-0002-3635-2003
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 16 July 2025
First Online: 23 July 2025
Change Date: 4 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12265-025-10674-3
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and followed the Declaration of Helsinki for ethical standards in research with humans. The study was approved by the Mayo Clinic Institutional Review Board (IRB protocol # 17–003392).
: Due to its retrospective nature, informed consent was waived by the Mayo Clinic’s Institutional Review Board.
: No animal studies were carried out by the authors for this article.
: Not applicable.
: Dr. Ackerman is a consultant for Abbott, BioMarin Pharmaceutical, Boston Scientific, Bristol Myers Squibb, Illumina, Invitae, Medtronic, Tenaya Therapeutics, and UpToDate. Dr. Ackerman and Mayo Clinic are/were involved in an equity/intellectual property/royalty relationship with AliveCor, Anumana, ARMGO Pharma, Prolaio, Solid Biosciences, and Thryv Therapeutics.Dr. Giudicessi is a consultant for Avidity Biosciences and Citizen Health, has Grants/Clinical Trials sponsored by Tenaya Therapeutics, and has Equity/Royalty in Prolaio through Mayo Clinic Ventures.Remaining authors have no other disclosures.
